$SLS Cashflow Statement | Understand Stock

$SLS

$12.18 +$0.01 (0.08%) Pre-market

$SLS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustment to reconcile net loss to net cash used in operating activities:
Acquired in-process research and development
Non-cash in-process research and development impairment charge
Acquired in-process research and development charge
Non-cash stock-based compensation
Non-cash lease expense
Change in fair value of contingent consideration
Change in fair value of common stock warrants
Deferred income taxes
Changes in operating assets and liabilities:
Contract asset
Prepaid expenses and other assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities
Deferred revenue

Net cash used in operating activities
Cash paid for acquisition of in-process research and development
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs
Proceeds from warrant inducements, net of issuance costs
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs
Proceeds from the exercise of common stock warrants and pre-funded warrants
Collection of stock subscription receivable
Proceeds from employee stock plan purchases
Tax withholding on vesting of restricted stock units
Net cash provided by financing activities

Net increase in cash, cash equivalents, restricted cash, and restricted cash equivalents
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of year
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of year
Supplemental disclosure of cash flow information:
Cash received during the year for interest
Supplemental disclosures:
Contract asset within accounts payable
Reclassification of warrant liabilities upon exercise
Deferred offering costs included in accounts payable and accrued expenses
Payable for acquired in-process research and development
Fair value of common stock warrants issued in warrant inducements
Warrant modifications recorded in stockholders' equity
Increase in operating lease right of use assets and current and non-current operating lease liabilities
Offering costs in accounts payable and accrued expenses

Comments